• en
  • fr
  • A World Renowed MultidisciplinaryTeam of top Scientists

    Since 2001, a network of 180 professionals including biomedical engineers, biochemists, microbiologists, pathologists, oncologists, radiologists, veterinarians, software engineers and other science and healthcare professionals have been working together to deliver an innovative solution to a dire need.

    180 Professionals
    17 Years In Development



    Starpax addresses two fundamental issues that have been hindering major advances in cancer treatment:

    Problem No


    The inefficiency of systemic treatments During a systemic injection of drugs:

    • 0.7%
      of the injected drugs reaches the tumor
    • 99.3%
      of the toxic drugs spread throughout the whole body attacking healthy tissues and organs

    Problem No


    Unreachable cancer stem cells in the low-oxygen region (hypoxic zones)

    • The hardest to treat
    • They create shields around themselves
    • It is practically impossible to reach and destroy all the cancer stem cells using systemic treatment because hypoxic zones are not vascularized,



    The Transporter

    Starpax Bn1-S™ bacteria

    The Starpax live bacterium, known as Bn1-S ™, is a unique transporter. It has been specifically created in laboratory through more than 800 controlled mutations over a 12-year period to respond precisely to the needs of the Starpax technology.

    Some characteristics of the Bn1-S™ bacterium:

    • Swims by itself;
    • Controlled by magnetic fields;
    • Up to 2 microns in size, capable of traveling through interstitial layers of human tissue; does not require bloodstream to travel;
    • It is grown in very low-oxygen environments similar to the hypoxic zone of cancerous tumors;
    • Non-pathogenic;
    • Dies after appx. 30 minutes at body temp. of 37ºC;
    • Does not reproduce in the body.

    Therapeutic cancer agents are attached to the bacteria

    Starpax Bn1-S™ bacteria loaded with drugs

    The agents are inserted into liposomes (chemical spheres) and attached to the bacteria.

    • Starpax does not develop drugs; 
    • we use already approved drugs. But with a single injection, the Starpax transporters can deliver into the tumor up to 50 times the dose that standard chemotherapy treatment can do, and this, without spreading the drug in the whole body.

    The bacteria are injected

    Swarm of Starpax Bn1-S ™ bacteria

    Tens of million Starpax Bn1-S ™ bacteria are loaded with the therapeutic agent and injected next to the tumor (not in the bloodstream).

    Injections cannot be made directly into the tumor, as it will create pressure in the tumor, creating a risk of pushing the cancer cells into the vascular system and seeding metastasis.

    The bacteria are guided into the tumor

    Magnetic fields of the Starpax 1000 guiding bacteria into the tumor

    The bacteria swim into the interstitial tissue and then are precisely guided into the tumor by the 3D magnetic fields of very low intensity generated by the Starpax 1000 Magnetotaxi™.


    The bacteria fill the tumor including the hypoxic zones

    Bacteria Inside a human Tumor

    The bacteria penetrate the hypoxic shield and deliver the drugs to the cancer stem cells

    Once inside the tumor, the Bn-1-S swim across the whole tumor seeking refuge into the low- oxygenated environment of the hypoxic zones. The liposomes are engineered to release at this time the therapeutic agents to all cancer cells including the stem cells in the hypoxic zones, and destroy them. The bacteria die a few minutes later.


    The preclinical tests already provided remarkable results. Starpax intends to initiate clinical trials with patients in hospitals in 2021.